Development status: Approved

Gram-positive activity

Combination therapy

Mechanism of Action/Target pathogen: Inhibits the synthesis of protein and cell wall lipid

Additional information: Nitroimidazopyran derivative. Developed for the treatment of multidrug-resistant Mycobacterium tuberculosis in combination with bedaquiline and linezolid.